MediWound, an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it ...

(NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare ...

MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...

Venous ulcers are the most common type of leg ulcer, often caused by weak veins or poor blood flow in the legs. If you have varicose veins or have had a leg injury, you might be at higher risk.

In one particular study involving three patients with leg ulcers, Dooms-Goossens and Degreef discovered that the patients reacted to petrolatums on their leg ulcers despite having negative patch ...

Venous leg ulcers affect about 2% of individuals aged 65 and older, with over 1.5 million new cases reported annually in the U.S., the company said. They typically develop on the lower extremities ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...

BioLab Holdings, Inc., a Phoenix-based medical manufacturer specializing in wound healing and wound care products, is pleased to announce the approval of its randomized control trial designed to ...